Free Trial
NASDAQ:WGS

GeneDx Q3 2025 Earnings Report

GeneDx logo
$124.05 -2.76 (-2.18%)
As of 12:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

GeneDx EPS Results

Actual EPS
N/A
Consensus EPS
$0.33
Beat/Miss
N/A
One Year Ago EPS
N/A

GeneDx Revenue Results

Actual Revenue
N/A
Expected Revenue
$104.33 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

GeneDx Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Tuesday, October 28, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

GeneDx Earnings Headlines

Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.tc pixel
See More GeneDx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GeneDx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GeneDx and other key companies, straight to your email.

About GeneDx

GeneDx (NASDAQ:WGS) is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care. In 2015, the company became a subsidiary of OPKO Health, leveraging OPKO’s global infrastructure to expand its testing capabilities and research collaborations. GeneDx holds College of American Pathologists (CAP) accreditation and is CLIA-certified, ensuring adherence to stringent quality and regulatory standards.

GeneDx serves a diverse client base that includes hospitals, academic medical centers, reference laboratories and pharmaceutical partners, as well as patients participating in research studies. While its primary market is the United States, the company also accommodates international referrals through its global network, enabling access to advanced genetic diagnostics for clinicians and patients worldwide. With a dedicated team of geneticists, laboratory scientists and genetic counselors, GeneDx continues to advance precision medicine by translating complex genomic data into actionable clinical insights.

View GeneDx Profile

More Earnings Resources from MarketBeat